India has agreed to supply to Malaysia hydroxychloroquine for the treatment of COVID-19
The government of India agreed to sell Malaysia hydroxychloroquine – antimalarial drug with potential efficacy against COVID-19. Earlier, new Delhi has partially lifted a temporary ban on the export of the drug, writes Reuters.
India is the largest manufacturer of hydroxychloroquine, sales worldwide have soared due to reports of potential antimalarial drug in the fight against coronavirus infection. The increased demand for the drug has forced India last month to impose a ban on the export of hydroxychloroquine, this ban was partially lifted after persistent requests from the United States. Now the authorities have allowed the export of 89,1 thousand tablets in Malaysia. This drug will be used by Malaysian doctors in the therapy of patients with easy and moderate for COVID-19.
Meanwhile in France, said the dangerous side effects of anti-malarial drug: in the country there were 42 adverse events of the heart with the use of hydroxychloroquine. Medical regulators have warned about the importance of observing caution in the use of experimental treatment coronavirus infection.
